1
Clinical Trials associated with Anti-GD2-800CW(Princess Maxima Centre For Ped)iatric OncologyA Phase Ib/II First-in-human Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients. The aim of this imaging study is to determine a safe and effective dose of anti-GD2-800CW for intra-operative detection of neuroblastoma using NIR fluorescence.
100 Clinical Results associated with Anti-GD2-800CW(Princess Maxima Centre For Ped)iatric Oncology
100 Translational Medicine associated with Anti-GD2-800CW(Princess Maxima Centre For Ped)iatric Oncology
100 Patents (Medical) associated with Anti-GD2-800CW(Princess Maxima Centre For Ped)iatric Oncology
100 Deals associated with Anti-GD2-800CW(Princess Maxima Centre For Ped)iatric Oncology